Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Public Citizen Xenical follow-up

This article was originally published in The Tan Sheet

Executive Summary

"Four researchers interviewed by the Cancer Letter objected to the fact that FDA advisory committee members who met on Jan. 23 to consider the over-the-counter switch of orlistat [GlaxoSmithKline's proposed OTC weight-loss drug, Alli] were not informed at or prior to the meeting about pre-cancerous changes...induced by orlistat in the colon of animals," Public Citizen states in a June 5 letter. The group submitted the letter as a supplement to its April 10 petition to ban the sale of Rx orlistat (Xenical), which also cited the link between the drug and the development of aberrant crypt foci (ACF) in rats (1"The Tan Sheet" April 17, 2006, p. 3). Although ACF may not have a causal link to polyps or colon cancer, it may be a surrogate marker for the disease. The group urges the inclusion of the animal ACF data in the agency's decision-making process on the drug and recommends that FDA remove the drug from the market...
Advertisement
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS099502

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel